Status: Recruiting
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.
Participants needed: 171
Trial details
Phase: Phase 3Age: 19+Biological sex: AllType: InterventionalSponsor: CelltrionUpdated: Aug 11, 2025Locations: 1
Eligibility criteria
Adults at the time of signing the Informed Consent Form (ICF) [+2]
Diagnosed with other types of diabetes than T2DM [+2]